IBM shares fall 23%: CEO says Q2 earnings fell short as customers spent more on AI

IBM shares plunged more than 23% Tuesday after preliminary Q2 results missed expectations. Adjusted EPS fell to $2.93 vs $3.01 expected (-$0.08, ~-2.7%), while revenue came in at $17.2B vs $17.86B expected (-$0.66B, ~-3.7%). The earnings and sales shortfall drove the stock’s steepest single-day decline in decades.

Analysis

This looks less like a one-off earnings miss and more like a credibility event: once a mature tech compounder breaks a long-held “defensive” profile, the market usually re-rates the entire earnings path, not just the quarter. The immediate loser is IBM itself, but the broader read-through is to legacy enterprise IT spend: consulting-heavy vendors and infrastructure-adjacent names like ACN, DXC, and HPE can see multiple compression if investors start assuming project deferrals are broadening rather than idiosyncratic.

The second-order effect is in capital allocation and customer behavior. If IBM’s mix weakness is coming from slower deal conversion, that typically precedes softer backlog conversion across the enterprise software/services stack by 1-2 quarters, while hyperscalers with consumption-based revenue (MSFT, AMZN, GOOGL) should be comparatively insulated. The key question is whether this is a timing issue or a demand issue; the stock’s magnitude suggests the market is pricing a structural reset, but that can reverse quickly if management proves the guide was conservative and margins/FCF hold.

From a risk standpoint, the near-term path is days to weeks: post-cap flushes often overshoot, especially in large-cap value names with crowded income-oriented ownership. Over 1-3 months, the catalyst is the next guidance update and any evidence on bookings/backlog; over 6-18 months, the issue is whether IBM can still defend its premium multiple as a slow-growth, cash-return story. The contrarian view is that the selloff may be overdone if the miss was driven by timing in software/license revenue rather than demand destruction; that would argue for fading further downside only after the next print confirms stabilization.

Key Decisions for Investors

• Fade strength in IBM rather than chase the gap-down: sell into 5-10% relief rallies over the next 1-3 weeks; the stock needs clear evidence of guide stability to re-rate.
• If options liquidity is usable, buy a 1-3 month IBM put spread instead of outright shorting; the event has already repriced a lot of bad news, so convex downside with defined risk is preferable.
• Pair trade: long ACN / short IBM for 1-3 months if the thesis is relative execution quality in enterprise services; IBM must show backlog durability before the spread is justified on its own.
• Watch HPE and DXC as lower-quality read-throughs on enterprise spending; if those names also weaken into earnings, it would confirm a broader budget-deferment cycle and extend the downside thesis.
• Falsifier: if IBM’s next guidance update implies stable-to-improving revenue growth and no margin/FCF damage, cover tactical shorts quickly; the selloff would likely be a valuation reset rather than a fundamental break.